Lisinopril

Lisinopril is an ACE inhibitor (angiotensin-converting enzyme inhibitor), a medicine taken by mouth. The US label read, for ZESTRIL tablets (lisinopril), lists three uses: treating high blood pressure in adults (and, for pediatric patients 6 years and older, in a separate statement), adding to other treatment of heart failure to reduce signs and symptoms of systolic heart failure, and reducing deaths when started within 24 hours of an acute myocardial infarction in people whose condition is stable. Zestril is the brand name on the label read.

Also called Zestril

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 29046; UNII E7199S1YWR. The label describes the ingredient as lisinopril dihydrate, so UNII E7199S1YWR is the UNII of the dihydrate form and is a broad match. MeSH descriptor D017706 is Lisinopril. Class: Angiotensin Converting Enzyme Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Upsher-Smith Laboratories, LLC label for ZESTRIL (lisinopril) tablets, application NDA019777, effective 2025-01-02 in openFDA; Drugs@FDA lists the application's sponsor as TWI PHARMS. Other lisinopril labels, including the Qbrelis oral solution label, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 6 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
6
Phase 3 or 4
5
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedTerminatedUnknown statusAll statuses
Phase 21001
Phase 30101
Phase 42114
All phases3216

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 1 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII E7199S1YWR

Claims and evidence

Context Children for whom the US label of lisinopril (Zestril) lists hypertension as an indication: pediatric patients 6 years of age and older

Recipient
Child
Population
Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Label wording: pediatric patients 6 years of age and older
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Children with hypertension (pediatric patients 6 years of age and older)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in pediatric patients 6 years of age and older.

    Applies to Child Children for whom the US label of lisinopril (Zestril) lists hypertension as an indication: pediatric patients 6 years of age and older

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250102.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients for whom the US label of lisinopril (Zestril) lists an indication: adult hypertension, systolic heart failure, acute myocardial infarction within 24 hours

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The hypertension indication names adults (and, separately, pediatric patients 6 years and older); the heart failure and myocardial infarction indications do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults for hypertension, as the passage read states; not stated for the other indications
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
  • Adult patients with hypertension
  • Patients with systolic heart failure, as adjunct therapy
  • Hemodynamically stable patients within 24 hours of acute myocardial infarction
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in adults (the same label sentence also names pediatric patients, recorded separately); as adjunct therapy for heart failure, to reduce signs and symptoms of systolic heart failure; and for the reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction.

    Applies to Recipient not specified Patients for whom the US label of lisinopril (Zestril) lists an indication: adult hypertension, systolic heart failure, acute myocardial infarction within 24 hours

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (5)
    1. Supports openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[2], 1.2 Heart Failure
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[3], 1.3 Reduction of Mortality in Acute Myocardial Infarction
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Background openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250102.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Background openFDA Drugs@FDA record for application NDA019777 (ZESTRIL, sponsor TWI PHARMS): product and sponsor

      Regulator · U.S. Food and Drug Administration (openFDA, Drugs@FDA) · Edition The openFDA Drugs@FDA record for application NDA019777, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.

      Locator
      results[0].products[0].brand_name
      How it applies
      Drugs@FDA product listing for application NDA019777, which confirms the product the label belongs to.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      10404252bca5ef727ea05a4ea88c2e77deb09478b9d3791d6f5084684cf291f1
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In newborns, infants and children 1

Claims whose context is a newborn, an infant or a child.

  • Description Evidence stage not applicable Certainty not assessed

    The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in pediatric patients 6 years of age and older.

    Applies to Child Children for whom the US label of lisinopril (Zestril) lists hypertension as an indication: pediatric patients 6 years of age and older

    Population, setting and follow-up
    • Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Label wording: pediatric patients 6 years of age and older
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that names children in the hypertension indication, quoted in the research quote table.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250102.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

PRINIVIL

No label from the application holder was found in the openFDA label dataset for application NDA019558. This page does not show another labeler's label in its place.

PRINZIDE

No label from the application holder was found in the openFDA label dataset for application NDA019778. This page does not show another labeler's label in its place.

QBRELIS

No label from the application holder was found in the openFDA label dataset for application NDA208401. This page does not show another labeler's label in its place.

ZESTORETIC

No label from the application holder was found in the openFDA label dataset for application NDA019888. This page does not show another labeler's label in its place.

ZESTRIL

No label from the application holder was found in the openFDA label dataset for application NDA019777. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA019558 PRINIVIL
  2. Approval NDA019777 ZESTRIL
  3. Approval NDA019778 PRINZIDE
  4. Approval NDA019888 ZESTORETIC
  5. Supplemental approval NDA019777 ZESTRIL
  6. Supplemental approval NDA019558 PRINIVIL
  7. Supplemental approval NDA019778 PRINZIDE
  8. Supplemental approval NDA019888 ZESTORETIC
  9. Supplemental approval NDA019558 PRINIVIL
  10. Supplemental approval NDA019777 ZESTRIL
  11. Supplemental approval NDA019777 ZESTRIL
  12. Supplemental approval NDA019558 PRINIVIL
  13. Supplemental approval NDA019777 ZESTRIL
  14. Approval NDA208401 QBRELIS

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 5

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.

    ProductNDA019558

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.

    ProductNDA019777

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA019778

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA019888

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA208401

Registry trials 6

Record details

Record id
cardio:lisinopril
Content hash
3232d527bcb89d64232242a9c0fe287af3d04c449800c2e32589cb38310a826d